Randomized trial reveals aspirin prevents serious vascular events in diabetes but increases major bleeding, indicating that bleeding risks counterbalance its cardiovascular benefits.
Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard. (Funded by the British Heart Foundation and others; ASCEND Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).
No takes yet. Share an insight, caveat, or question.
the ASCEND Study Collaborative Group (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: